Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Sponsor: Acerus Pharmaceuticals Corporation
This PHASE3 trial investigates Male Hypogonadism and is currently completed. Acerus Pharmaceuticals Corporation leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Unknown Status PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Feb 2017 — Feb 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acerus Pharmaceuticals Corporation
For direct contact, visit the study record on ClinicalTrials.gov .